Summary Affibody AB (Affibody) is a biotechnology company that focuses on the development of next generation biopharmaceuticals based on its proprietary technology platforms, namely, Affibody molecules and Albumod, the half-life extension technology. The company's Affibody molecules are a class of antibody mimetics, which surpass monoclonal antibodies and antibody fragments; and Albumod technology is designed to enhance the efficacy of biopharmaceuticals. Affibody's pipeline projects include SOBI002 (C5), AFB-035 and IL-1 biology, for inflammation and autoimmune disorders; HER2 radiotherapy, for cancer; ABY-025/GE226 and ABY-026, for cancer diagnostics; and others. Some of the company's major partners include Amylin, Daiichi Sankyo, Daewoong, Swedish Orphan Biovitrum, GE Healthcare and others. Affibody is headquartered in Solna, Sweden. Affibody AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data... Research Beam Model: Research Beam Product ID: 1746989 250 USD New
Affibody AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile.
 
 

Affibody AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

  • Category : Pharmaceuticals
  • Published On : July   2017
  • Pages : 28
  • Publisher : GlobalData
 
 
 
Summary

Affibody AB (Affibody) is a biotechnology company that focuses on the development of next generation biopharmaceuticals based on its proprietary technology platforms, namely, Affibody molecules and Albumod, the half-life extension technology. The company's Affibody molecules are a class of antibody mimetics, which surpass monoclonal antibodies and antibody fragments; and Albumod technology is designed to enhance the efficacy of biopharmaceuticals. Affibody's pipeline projects include SOBI002 (C5), AFB-035 and IL-1 biology, for inflammation and autoimmune disorders; HER2 radiotherapy, for cancer; ABY-025/GE226 and ABY-026, for cancer diagnostics; and others. Some of the company's major partners include Amylin, Daiichi Sankyo, Daewoong, Swedish Orphan Biovitrum, GE Healthcare and others. Affibody is headquartered in Solna, Sweden.

Affibody AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Affibody AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Affibody AB, Medical Devices Deals, 2011 to YTD 2017 9
Affibody AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Affibody AB, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nordic Nanovector Enters into Co-Development Agreement with Affibody 11
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 11
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 12
Affibody Enters Into Co-Development Agreement With Nuclisome 13
Licensing Agreements 14
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 14
Affibody Enters into Licensing Agreement with Biotest 15
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 16
AbClon Enters into Licensing Agreement with Affibody 16
Affibody Enters into Licensing Agreement with Daewoong Pharma for Albumod 17
Algeta Enters Into Licensing Agreement With Affibody 18
Affibody AB - Key Competitors 20
Key Employees 21
Locations And Subsidiaries 22
Head Office 22
Recent Developments 23
Financial Announcements 23
Nov 18, 2016: Affibody Medical: Interim Report – January to September 2016 23
Aug 19, 2016: Affibody Medical: Interim Report – January to June 2016 24
May 20, 2016: Affibody Medical: Interim Report – January to March 2016 25
Feb 26, 2016: Affibody Medical: Year End Report 2015 26
Clinical Trials 27
May 04, 2016: Affibody Announces Initial Results from a Phase I Study of ABY-035 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Affibody AB, Pharmaceuticals & Healthcare, Key Facts 1
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Affibody AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Affibody AB, Deals By Therapy Area, 2011 to YTD 2017 8
Affibody AB, Medical Devices Deals, 2011 to YTD 2017 9
Affibody AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Nordic Nanovector Enters into Co-Development Agreement with Affibody 11
Swedish Orphan Biovitrum Enters Into Research Agreement With Affibody 11
Affibody Enters Into Co-Development Agreement With Creative Antibiotics 12
Affibody Enters Into Co-Development Agreement With Nuclisome 13
Swedish Orphan Biovitrum Exercises Option for Licensing Agreement with Affibody for IL-1 14
Affibody Enters into Licensing Agreement with Biotest 15
Affibody Enters Into Licensing Agreement With Daiichi Sankyo For Albumod 16
AbClon Enters into Licensing Agreement with Affibody 16
Affibody Enters into Licensing Agreement with Daewoong Pharma for Albumod 17
Algeta Enters Into Licensing Agreement With Affibody 18
Affibody AB, Key Competitors 20
Affibody AB, Key Employees 21
List of Figures
Affibody AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Affibody AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Affibody AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Affibody AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Affibody AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Affibody AB, Medical Devices Deals, 2011 to YTD 2017 9
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter